Compare Novartis AG (NVS) vs Unum Group Common Stock (UNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Unum Group Common Stock — how do they compare? Novartis AG trades at $149.44 (market cap $279.90B), while Unum Group Common Stock trades at $91.42 (market cap $14.48B). The key difference: Novartis AG is far larger — about 19.3× Unum Group Common Stock's market cap, and Novartis AG pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Unum Group Common Stock for 0 Days on average.
| NVS | UNM | |
|---|---|---|
Market Cap | $279.90B | $14.48B |
Volume | 1,647,300 | 2,214,044 |
Sector | Health | Financials |
52-Week High | $168.62 | $96.57 |
52-Week Low | $121.80 | $70.66 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $321.22B | $18.04B |
Dividend Yield | 3.23% | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $142.41, down 0.99% with a bearish technical signal despite strong fundamentals including 74.74% gross margins and 30.55% ROE. Recent Q2 2026 EPS beat expectations at $2.41 versus $2.17, though Q1 missed. The company announced a $7.8B licensing deal with China's Abogen for mRNA therapy, while facing clinical setbacks in ALS drug development and investor scrutiny over M&A strategy.
The stock presents a mixed outlook with solid profitability and growth potential from new deals, but technical weakness and recent trial failures pose near-term risks. Analyst consensus at $146 target suggests modest upside, though bearish sentiment from 68% hold ratings indicates caution amid pipeline uncertainties and competitive pressures in pharma.
Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.
UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Unum Group Common Stock
Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.
Read more on UNM →
